the present invention relates to antibodies) that specifically bind to proteins lamp1 (membrane protein 1 is associated with more human and macaca fascicularis) and immunoconjugu u00e9s co.the antibody conjugates mprenant or related to a growth inhibitory agent.the present invention relates to pharmaceutical compositions comprising the antibodies of the invention or immunoconjugu u00e9s and the use of the antibody or the immunoconjugu u00e9sthe treatment of cancer, as well as lamp1 antibodies, nucleic acids isolated.vectors and host cells comprising a sequence coding for said antibody and use of the antibodies as a diagnostic tool.the present application relates to the detection of the amplification of a gene lamp1 or increase in cancer cells, leading to the determination of the susceptibility of patients weints cancer to respond to anti lamp1 therapy.the present invention relates to a method, therefore, in vitro selection of cancer patients, the method comprising determining.in a biological sample taken from a patient with cancer and cancer cells.the presence or absence of an increase in the number of copies of the gene in the patient lamp1； and the selection of the patient on the basis of the presence of an increase in the number of copies of the gene lamp1.the present invention relates to a therapeutic agent and anti lamp1 for use in the treatment of cancer in a patient with an increase in the number of copies of the gene lamp1 is present.)la présente invention concerne des anticorps qui se lient spécifiquement aux protéines lamp1 (protéine-1 de membrane associée au lysosome) humaines et de macaca fascicularis et des immunoconjugués comprenant lesdits anticorps conjugués ou liés à un agent d'inhibition de la croissance. La présente invention concerne également des compositions pharmaceutiques comprenant des anticorps ou des immunoconjugués de l'invention et l'utilisation des anticorps ou des immunoconjugués pour le traitement du cancer, ainsi que des anticorps an
